Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bisoprolol + candesartan
- Development stage
- Unknown
- Lead developer
- Midas Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Bisoprolol + candesartan is a fixed-dose combination (FDC) small molecule therapy being developed by Midas Pharma for the treatment of hypertension and heart failure with impaired systolic left ventricular function. Bisoprolol is a cardioselective beta-1 adrenergic receptor blocker that reduces heart rate and myocardial contractility. Candesartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, leading to vasodilation and reduced aldosterone secretion. The combination aims to provide synergistic blood pressure control and improved outcomes in heart failure patients by targeting two distinct pathways in the cardiovascular system.
- Other names
- bisoprolol fumarate + candesartan cilexetil
02
Targets
KCNN4 (Intermediate conductance calcium-activated potassium channel protein 4)ADRB1 (β1)AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on bisoprolol + candesartan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bisoprolol + candesartan.